Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120287) titled 'dexamethasone and orelabrutinib in newly diagnosed primary immune thrombocytopenia' on March 11.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: HenanCancerHospital
Condition:
Primary immune thrombocytopenia
Intervention:
Experimental group:Orelabrutinib (50 mg qd po) combined with high-dose dexamethasone (40 mg qd for 4 days)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-11
Target Sample Size: Experimental group:33;Control group:33;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=313103...